Lifespin Announces the Launch of its First Commercial Product in Regulated Healthcare
Lifespin Amino Acid Profiler™
Press and media
Lifespin partners with the Leipzig Research Center for Civilization Diseases (LIFE) to obtain deep clinical insights for obesity and diabetes
8,000 patient samples to be digitized and studied for metabolic patterns
Lifespin Announces Inaugural Membership in the Industrial Participant Program of the Wyss Diagnostics Accelerator at Harvard University
Wyss Diagnostics Accelerator seeks to fast-track disruptive diagnostic technologies to meet unmet critical needs
Lifespin Granted ISO13485 Certification for Its Proprietary A.I.-based Metabolomics Platform for In Vitro Diagnostics
ISO13485 certification represents a key milestone towards achieving market-readiness of its automated, high-volume testing infrastructure and ability to build affordable and scalable omics-based precision medicine tools
New Tech Could Improve Diagnostic Accuracy of Prostate Cancer Tests
Dr. Ali Tinazli’s article about “New Tech Could Improve Diagnostic Accuracy of Prostate Cancer Tests”
The Crucial Role Of Predictive Analytics In Precision Medicine
Dr. Ali Tinazli’s post at the Forbes magazine about “The Crucial Role Of Predictive Analytics In Precision Medicine”
History Of Health Technologies And Meaningful Change In The Era Of Health 4.0
Dr. Ali Tinazli’s post at the Forbes magazine about “History Of Health Technologies And Meaningful Change In The Era Of Health 4.0”
How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis
Dr. Ali Tinazli’s post at the Forbes magazine about “How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis”
Lifespin Announces Expansion of Laboratory Testing Capability
New investments in testing infrastructure will enable Lifespin to analyze up to 300,000 patient samples annually to support its metabolic profiling services BOSTON–(BUSINESS WIRE)–Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples per year. “These additional resources will support our recently launched commercial services which, for …
Lifespin Announces Expansion of Laboratory Testing Capability Read More »
Lifespin Launches Commercial Access to its Metabolic Profiler Software and Database for Pharma and Biobank Services
New commercial services will provide powerful insights to aid in research, development, and manufacturing by pharmaceutical companies and biobanks. BOSTON, MA, September 13, 2022 — Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has launched a new commercial service for the pharmaceutical and biobanking industry to assist companies in key phases of research, development, and manufacturing. Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid …